Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Pharmacy
Published in: International Journal of Clinical Pharmacy 3/2012

01-06-2012 | Review Article

Outpatient parenteral antimicrobial therapy with ceftriaxone, a review

Authors: Christopher J. A. Duncan, David A. Barr, R. Andrew Seaton

Published in: International Journal of Clinical Pharmacy | Issue 3/2012

Login to get access

Abstract

Background More than 30 years since it was developed for clinical use, the third-generation cephalosporin ceftriaxone remains the most commonly used agent for outpatient parental antimicrobial therapy (OPAT). Recent antimicrobial stewardship programmes have tended to restrict ceftriaxone use in hospitals to control antibiotic resistance and outbreaks of Clostridium difficle infection (CDI). Considering the expansion of OPAT programmes both in the UK and worldwide, revisiting the role of ceftriaxone in OPAT in the context of changing antimicrobial prescribing practices is timely. Aim of the review To identify the evidence base for OPAT, review current and historical data on indications for, and safety of ceftriaxone within the OPAT setting, and to provide some perspectives on the future role of ceftriaxone. Method We searched PubMed and Scopus for articles published in English, and hand searched reference lists. We also conducted a complementary descriptive analysis of prospectively acquired data on the use of ceftriaxone in more than 1,300 OPAT episodes over a 10-year period in our UK centre. Results Ceftriaxone has an excellent safety profile in the OPAT setting, and its broad spectrum of activity makes it an established agent in a wide range of clinical infection syndromes, such as skin and soft-tissue infection, bone and joint infection, streptococcal endocarditis and several others. Intriguingly, in contrast to the inpatient setting, liberal use of ceftriaxone in OPAT has not been strongly linked to CDI, suggesting additional patient and environmental factors may be important in mediating CDI risk.
Literature
1.
Newton GG, Abraham EP, Cephalosporin C. a new antibiotic containing sulphur and D-alpha-aminoadipic acid. Nature. 1955;175(4456):548.PubMedCrossRef
2.
3.
Reiner R, Weiss U, Brombacher U, Lanz P, Montavon M, Furlenmeier A, et al. Ro 13-9904/001, a novel potent and long-acting parenteral cephalosporin. J Antibiot (Tokyo). 1980;33(7):783–6.CrossRef
4.
Esposito S. Parenteral cephalosporin therapy in ambulatory care: advantages and disadvantages. Drugs. 2000;59(Suppl 3):19–28. (discussion 47–49).PubMedCrossRef
5.
Esposito S, Noviello S, Leone S, Tice A, Seibold G, Nathwani D, et al. Outpatient parenteral antibiotic therapy (OPAT) in different countries: a comparison. Int J Antimicrob Agents. 2004;24(5):473–8.PubMedCrossRef
6.
Paladino JA, Poretz D. Outpatient parenteral antimicrobial therapy today. Clin Infect Dis. 2010;51(Suppl 2):S198–208.PubMedCrossRef
7.
Eron LJ, Park CH, Hixon DL, Goldenberg RI, Poretz DM. Ceftriaxone therapy of bone and soft tissue infections in hospital and outpatient settings. Antimicrob Agents Chemother. 1983;23(5):731–7.PubMedCrossRef
8.
9.
Bernstein Hahn L, Barclay CA, Iribarren MA, Traballi CA. Ceftriaxone, a new parenteral cephalosporin, in the treatment of urinary tract infections. Chemotherapy. 1981;27(Suppl 1):75–9.PubMedCrossRef
10.
Eichmann A, Weidmann G, Havas L. One-dose treatment of acute uncomplicated gonorrhoea of male patients with ceftriaxone Ro 13-9904, a new parenteral cephalosporin. A dose-range finding pilot study using doses of 500, 250, 125 and 50 mg respectively, in descending order. Chemotherapy. 1981;27(Suppl 1):62–9.PubMedCrossRef
11.
Baumgartner JD, Glauser MP. Single daily dose treatment of severe refractory infections with ceftriaxone. Cost savings and possible parenteral outpatient treatment. Arch Intern Med. 1983;143(10):1868–73.PubMedCrossRef
12.
Handsfield HH, Murphy VL. Comparative study of ceftriaxone and spectinomycin for treatment of uncomplicated gonorrhoea in men. Lancet. 1983;2(8341):67–70.PubMedCrossRef
13.
Poretz DM, Woolard D, Eron LJ, Goldenberg RI, Rising J, Sparks S. Outpatient use of ceftriaxone: a cost-benefit analysis. Am J Med. 1984;77(4C):77–83.PubMed
14.
Tice AD. Once-daily ceftriaxone outpatient therapy in adults with infections. Chemotherapy. 1991;37(Suppl 3):7–10.PubMedCrossRef
15.
Tice AD. International outpatient parenteral antimicrobial therapy. Int J Clin Pract Suppl. 2000;115:26.PubMed
16.
Torok ME, Chapman AL, Lessing MP, Sanderson F, Seaton RA. Outpatient parenteral antimicrobial therapy: recent developments and future prospects. Curr Opin Investig Drugs. 2010;11(8):929–39.PubMed
17.
Russo TA, Cook S, Gorbach SL. Intramuscular ceftriaxone in home parenteral therapy. Antimicrob Agents Chemother. 1988;32(9):1439–40.PubMedCrossRef
18.
Chapman AL, Dixon S, Andrews D, Lillie PJ, Bazaz R, Patchett JD. Clinical efficacy and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspective. J Antimicrob Chemother. 2009;64(6):1316–24.PubMedCrossRef
19.
Caplan GA, Ward JA, Brennan NJ, Coconis J, Board N, Brown A. Hospital in the home: a randomised controlled trial. Med J Aust. 1999;170(4):156–60.PubMed
20.
Corwin P, Toop L, McGeoch G, Than M, Wynn-Thomas S, Wells JE, et al. Randomised controlled trial of intravenous antibiotic treatment for cellulitis at home compared with hospital. Bmj. 2005;330(7483):129.PubMedCrossRef
21.
Shepperd S, Doll H, Angus RM, Clarke MJ, Iliffe S, Kalra L, et al. Admission avoidance hospital at home. Cochrane Database Syst Rev. 2008;(4):CD007491.
22.
Nathwani D, Tice A. Ambulatory antimicrobial use: the value of an outcomes registry. J Antimicrob Chemother. 2002;49(1):149–54.PubMedCrossRef
23.
Wynn M, Dalovisio JR, Tice AD, Jiang X. Evaluation of the efficacy and safety of outpatient parenteral antimicrobial therapy for infections with methicillin-sensitive Staphylococcus aureus. South Med J. 2005;98(6):590–5.PubMedCrossRef
24.
Matthews PC, Conlon CP, Berendt AR, Kayley J, Jefferies L, Atkins BL, et al. Outpatient parenteral antimicrobial therapy (OPAT): is it safe for selected patients to self-administer at home? A retrospective analysis of a large cohort over 13 years. J Antimicrob Chemother. 2007;60(2):356–62.PubMedCrossRef
25.
Esposito S, Leone S, Noviello S, Ianniello F, Fiore M, Russo M, et al. Outpatient parenteral antibiotic therapy for bone and joint infections: an Italian multicenter study. J Chemother. 2007;19(4):417–22.PubMed
26.
Mackintosh CL, White HA, Seaton RA. Outpatient parenteral antibiotic therapy (OPAT) for bone and joint infections: experience from a UK teaching hospital-based service. J Antimicrob Chemother. 2011;66(2):408–15.PubMedCrossRef
27.
Gesser RM, McCarroll KA, Woods GL. Evaluation of outpatient treatment with ertapenem in a double blind controlled clinical trial of complicated skin/skin structure infections. J Infect. 2004;48(1):32–8.PubMedCrossRef
28.
Rehm S, Campion M, Katz DE, Russo R, Boucher HW. Community-based outpatient parenteral antimicrobial therapy (CoPAT) for Staphylococcus aureus bacteraemia with or without infective endocarditis: analysis of the randomized trial comparing daptomycin with standard therapy. J Antimicrob Chemother. 2009;63(5):1034–42.PubMedCrossRef
29.
Amodeo MR, Clulow T, Lainchbury J, Murdoch DR, Gallagher K, Dyer A, et al. Outpatient intravenous treatment for infective endocarditis: safety, effectiveness and one-year outcomes. J Infect. 2009;59(6):387–93.PubMedCrossRef
30.
Seaton RA, Bell E, Gourlay Y, Semple L. Nurse-led management of uncomplicated cellulitis in the community: evaluation of a protocol incorporating intravenous ceftriaxone. J Antimicrob Chemother. 2005;55(5):764–7.PubMedCrossRef
31.
Seaton RA, Sharp E, Bezlyak V, Weir CJ. Factors associated with outcome and duration of therapy in outpatient parenteral antibiotic therapy (OPAT) patients with skin and soft-tissue infections. Int J Antimicrob Agents. 2011;38(3):243–8.PubMedCrossRef
32.
Nathwani D. The management of skin and soft tissue infections: outpatient parenteral antibiotic therapy in the United Kingdom. Chemotherapy. 2001;47(Suppl 1):17–23.PubMedCrossRef
33.
Tice AD. Pharmacoeconomic considerations in the ambulatory use of parenteral cephalosporins. Drugs. 2000;59(Suppl 3):29–35. (discussion 47–49).PubMedCrossRef
34.
Eron LJ, Goldenberg RI, Poretz DM. Combined ceftriaxone and surgical therapy for osteomyelitis in hospital and outpatient settings. Am J Surg. 1984;148(4A):1–4.PubMed
35.
Mauceri AA. Treatment of bone and joint infections utilizing a third-generation cephalosporin with an outpatient drug delivery device. HIAT Study Group. Am J Med. 1994;97(2A):14–22.PubMedCrossRef
36.
Tice AD, Hoaglund PA, Shoultz DA. Risk factors and treatment outcomes in osteomyelitis. J Antimicrob Chemother. 2003;51(5):1261–8.PubMedCrossRef
37.
Francioli PB. Ceftriaxone and outpatient treatment of infective endocarditis. Infect Dis Clin North Am. 1993;7(1):97–115.PubMed
38.
Francioli P, Etienne J, Hoigne R, Thys JP, Gerber A. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone sodium for 4 weeks. Efficacy and outpatient treatment feasibility. JAMA. 1992;267(2):264–7.PubMedCrossRef
39.
Cervera C, del Rio A, Garcia L, Sala M, Almela M, Moreno A, et al. Efficacy and safety of outpatient parenteral antibiotic therapy for infective endocarditis: a ten-year prospective study. Enferm Infecc Microbiol Clin. 2011;29(8):587–92.PubMedCrossRef
40.
Larioza J, Heung L, Girard A, Brown RB. Management of infective endocarditis in outpatients: clinical experience with outpatient parenteral antibiotic therapy. South Med J. 2009;102(6):575–9.PubMedCrossRef
41.
Popescu GA. The long journey of outpatient parenteral antibiotic therapy in infective endocarditis: from idea to clinical guidelines. South Med J. 2009;102(6):559–60.PubMedCrossRef
42.
Tice AD. Safety of outpatient parenteral antimicrobial therapy for endocarditis. Clin Infect Dis. 2002;34(3):419–20.PubMedCrossRef
43.
Monteiro CA, Cobbs CG. Outpatient management of infective endocarditis. Curr Infect Dis Rep. 2001;3(4):319–27.PubMedCrossRef
44.
Andrews MM, von Reyn CF. Patient selection criteria and management guidelines for outpatient parenteral antibiotic therapy for native valve infective endocarditis. Clin Infect Dis. 2001;33(2):203–9.PubMedCrossRef
45.
Steele RW. Ceftriaxone therapy of meningitis and serious infections. Am J Med. 1984;77(4C):50–3.PubMed
46.
Martin E. Once-daily administration of ceftriaxone in the treatment of meningitis and other serious infections in children. Eur J Clin Microbiol. 1983;2(5):509–15.PubMedCrossRef
47.
Faella F, Pagliano P, Fusco U, Attanasio V, Conte M. Combined treatment with ceftriaxone and linezolid of pneumococcal meningitis: a case series including penicillin-resistant strains. Clin Microbiol Infect. 2006;12(4):391–4.PubMedCrossRef
48.
O’Connell S. Lyme borreliosis: current issues in diagnosis and management. Curr Opin Infect Dis. 2010;23(3):231–5.PubMedCrossRef
49.
Ljostad U, Skogvoll E, Eikeland R, Midgard R, Skarpaas T, Berg A, et al. Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial. Lancet Neurol. 2008;7(8):690–5.PubMedCrossRef
50.
Mogabgab WJ. Single-dose oral temafloxacin versus parenteral ceftriaxone in the treatment of gonococcal urethritis/cervicitis. Am J Med. 1991;91(6A):145S–9S.PubMedCrossRef
51.
Reusser P, Serex P. Outpatient treatment of gonorrhea with ceftriaxone. J Chemother. 1989;1(4 Suppl):895–6.PubMed
52.
Collier AC, Judson FN, Murphy VL, Leach LA, Root CJ, Handsfield HH. Comparative study of ceftriaxone and spectinomycin in the treatment of uncomplicated gonorrhoea in women. Am J Med. 1984;77(4C):68–72.PubMed
53.
Chisholm SA, Alexander S, Desouza-Thomas L, Maclure-Webster E, Anderson J, Nichols T, et al. Emergence of a Neisseria gonorrhoeae clone showing decreased susceptibility to cefixime in England and Wales. J Antimicrob Chemother. 2011;66(11):2509–12.PubMedCrossRef
54.
Carannante A, Prignano G, Cusini M, Matteelli A, Dal Conte I, Ghisetti V, et al. Cefixime and ceftriaxone susceptibility of Neisseria gonorrhoea in Italy from 2006 to 2010. Clin Microbiol Infect. 2011.
55.
Martin I, Jayaraman G, Wong T, Liu G, Gilmour M. Trends in antimicrobial resistance in Neisseria gonorrhoeae isolated in Canada: 2000–2009. Sex Transm Dis. 2011;38(10):892–8.PubMedCrossRef
56.
Butler T. Treatment of typhoid fever in the 21st century: promises and shortcomings. Clin Microbiol Infect. 2011;17(7):959–63.PubMedCrossRef
57.
Beeching NJ, Parry CM. Outpatient treatment of patients with enteric fever. Lancet Infect Dis. 2011;11(6):419–21.PubMedCrossRef
58.
White B, Coia JE, Sykes C, Mather H, Seaton RA. Enteric fever in returning travellers: role of outpatient parenteral antibiotic therapy. J Infect. 2012;64(2):242–5.PubMedCrossRef
59.
60.
Bijie H, Kulpradist S, Manalaysay M, Soebandrio A. In vitro activity, pharmacokinetics, clinical efficacy, safety and pharmacoeconomics of ceftriaxone compared with third and fourth generation cephalosporins: review. J Chemother. 2005;17(1):3–24.PubMed
61.
Lamb HM, Ormrod D, Scott LJ, Figgitt DP. Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections. Drugs. 2002;62(7):1041–89.PubMedCrossRef
62.
Boggs SR, Cunnion KM, Raafat RH. Ceftriaxone-induced hemolysis in a child with lyme arthritis: a case for antimicrobial stewardship. Pediatrics. 2011;128(5):e1289–92.PubMedCrossRef
63.
Kapur G, Valentini RP, Mattoo TK, Warrier I, Imam AA. Ceftriaxone induced hemolysis complicated by acute renal failure. Pediatr Blood Cancer. 2008;50(1):139–42.PubMedCrossRef
64.
Imam SN, Wright K, Bhoopalam N, Choudhury A. Hemolytic anemia from ceftriaxone in an elderly patient: a case report. J Am Med Dir Assoc. 2008;9(8):610–1.PubMedCrossRef
65.
Goyal M, Donoghue A, Schwab S, Hasbrouck N, Khojasteh S, Osterhoudt K. Severe hemolytic crisis after ceftriaxone administration. Pediatr Emerg Care. 2011;27(4):322–3.PubMedCrossRef
66.
Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med. 2007;146(9):657–65.PubMed
67.
Duncan CJ, Evans TJ, Seaton RA. Ceftriaxone-related agranulocytosis during outpatient parenteral antibiotic therapy. J Antimicrob Chemother. 2010;65(11):2483–4.PubMedCrossRef
68.
Patel R, Grogg KL, Edwards WD, Wright AJ, Schwenk NM. Death from inappropriate therapy for Lyme disease. Clin Infect Dis. 2000;31(4):1107–9.PubMedCrossRef
69.
Zishka PA, Douglas JM Jr. Immediate hypersensitivity reaction to single-dose parenteral ceftriaxone therapy for gonorrhea. Sex Transm Dis. 1991;18(1):26–7.PubMedCrossRef
70.
Pichichero ME. Use of selected cephalosporins in penicillin-allergic patients: a paradigm shift. Diagn Microbiol Infect Dis. 2007;57(3 Suppl):13S–8S.PubMedCrossRef
71.
Rienstra M, Bonten MJ, Gaillard CA. Ceftriaxone-associated biliary pseudolithiasis. Neth J Med. 2009;67(3):113–4.PubMed
72.
Karakitsos D, Poularas J, Samonis G, Karabinis A. Ceftriaxone-associated reversible biliary sludge in a critical care patient. Acta Anaesthesiol Scand. 2008;52(8):1171–2.PubMedCrossRef
73.
Martin E, Fanconi S, Kalin P, Zwingelstein C, Crevoisier C, Ruch W, et al. Ceftriaxone-bilirubin-albumin interactions in the neonate: an in vivo study. Eur J Pediatr. 1993;152(6):530–4.PubMedCrossRef
74.
Mohkam M, Karimi A, Gharib A, Daneshmand H, Khatami A, Ghojevand N, et al. Ceftriaxone associated nephrolithiasis: a prospective study in 284 children. Pediatr Nephrol. 2007;22(5):690–4.PubMedCrossRef
75.
Kimata T, Kaneko K, Takahashi M, Hirabayashi M, Shimo T, Kino M. Increased urinary calcium excretion caused by ceftriaxone: possible association with urolithiasis. Pediatr Nephrol. 2012;27(4):605–9.
76.
Owens RC Jr, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;46(Suppl 1):S19–31.PubMedCrossRef
77.
Kuntz JL, Chrischilles EA, Pendergast JF, Herwaldt LA, Polgreen PM. Incidence of and risk factors for community-associated Clostridium difficile infection: a nested case-control study. BMC Infect Dis. 2011;11:194.PubMedCrossRef
78.
Barr DA, Semple L, Seaton RA. Outpatient parenteral antimicrobial therapy (OPAT) in a teaching hospital-based practice: a retrospective cohort study describing experience and evolution over 10 years. Int J Antimicrob Agents. 2012;39(5):407-13.
79.
Schirmer PL, Deresinski SC. Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections. Expert Rev Anti Infect Ther. 2009;7(7):777–91.PubMedCrossRef
80.
Laudano JB. Ceftaroline fosamil: a new broad-spectrum cephalosporin. J Antimicrob Chemother. 2011;66(Suppl 3):iii11–iii18.
81.
Struelens MJ, Monnet DL. Prevention of methicillin-resistant Staphylococcus aureus infection: is Europe winning the fight? Infect Control Hosp Epidemiol. 2010;31(Suppl 1):S42–4.PubMedCrossRef
Metadata
Title
Outpatient parenteral antimicrobial therapy with ceftriaxone, a review
Authors
Christopher J. A. Duncan
David A. Barr
R. Andrew Seaton
Publication date
01-06-2012
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 3/2012
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-012-9637-z

Other articles of this Issue 3/2012

International Journal of Clinical Pharmacy 3/2012 Go to the issue

Case Report

Acute myocardial infarction and subacute stent thrombosis associated with cabazitaxel: a case report

Short Research Report

Characteristics of HIV patients referred to a medication adherence program in Switzerland

Research Article

Management of hypertension and factors affecting its control in Jordanian renal transplant recipients

Research Article

Effects of short-term addition of NSAID to diuretics and/or RAAS-inhibitors on blood pressure and renal function

Research Article

RETRACTED ARTICLE: Use of antidepressants and the risk of type 2 diabetes mellitus: a nested case–control study

Review Article

Review of services provided by pharmacies that promote healthy living
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits